better understand the impact of this new technology, we compared the SP and Multi-port (MP) platforms through objective measurement of cognitive load during the crucial steps of a robotic-assisted laparoscopic prostatectomy (RALP).
INTRODUCTION AND OBJECTIVES: Urological surgery is constantly searching for ways to improve outcomes in order to increase patient quality of life. Magnetic retraction has the potential to increase the benefits of minimally invasive surgery, as this innovative technology enhances exposure, meanwhile reducing invasiveness. The system allows for un-constrained, shaft-less magnetic retraction, overcoming the limitations of conventional surgical instruments. Early clinical results showed reduced pain, less complications, less scars and shorter length of hospital stay in general surgical procedures. This is the first prospective clinical trial that combines magnetic retraction in urological procedures. The purpose of this study was to evaluate the safety and effectiveness of the Levita Magnetic Surgical System (LMSS) in patients undergoing prostatectomy surgery.
METHODS: A prospective single-arm study was designed to assess the safety and effectiveness of the LMSS (Levita Magnetics, San Mateo CA) for prostatectomy. All adverse events (AE) were captured and summarized by relatedness to the device and/or procedure, seriousness and level of severity. The primary effectiveness endpoint was the ability to adequately retract the prostate to achieve an effective exposure of the target tissue. Adequate retraction was deemed to be achieved if it was not necessary to replace the LMSS with another instrument to perform the procedure.
RESULTS: The study was conducted following Good Clinical Practices and ISO 14155:2011(E). Local IRB approval was obtained and 30 subjects underwent surgery with the LMSS. All the cases were performed with 5 ports. The average procedure time was 3:23 (hours: minutes) and the average amount of time that the device was in the abdomen was 1:47. In all of the 30 cases, the LMSS was able to adequately retract the prostate (and/or peri-prostatic tissue) to achieve an effective exposure of the target tissue. 28 of 30 cases had organconfined disease, and a nerve sparing technique was effectively performed. Eleven AE were reported (ten mild and one moderate) and all resolved with no clinical sequelae. No AE was reported as device-related.
CONCLUSIONS: The study results demonstrate that the Magnetic Surgical System can be used in reduced port robotic-assisted laparoscopic prostatectomy surgery in a safe and effective manner. It is interesting to highlight that this new technology might provide assistance in preserving the nerve bundles in order to reduce incontinence and sexual dysfunction in prostatectomy patients. METHODS: Methods: Patients with progressive mCRPC (biochemical, radiographic or clinical) after >[1 novel androgen axis drug (NAAD), either chemotherapy (CTX) naive or post-CTX, with sufficient bone marrow reserve and normal kidney function were eligible. All patients underwent a screening PSMA PET/CT to confirm target expression. Patients received up to 4 cycles of 177Lu-PSMA-617 every 8 AE1 weeks and were randomized into 2 treatment activities groups (6.0 or 7.4 GBq). Kidney dosimetry was performed for the first cycle. Efficacy was defined as serum PSA decline of 50% from baseline at 12 weeks and served as primary endpoint. RESULTS: Results: 64 patients (median PSA 75 ng/ml; range 0.5-2425) were included in the study. 20% were CTX naive while 80% were post-CTX (1.9 CTX regimens on average, range 1-4). 45% completed 4 cycles of 177Lu-PSMA-617. Androgen deprivation therapy was given concomitantly in 83%, NAAD in 23% and immunotherapy in 6%.
PSA decline of >[50% was observed in 23% of patients at 12 weeks and in 38% of patients at any time (best PSA response). The median time to best PSA response was 22 weeks (range 6-49 weeks). 16% had a PSA decline of >[90% and 59% had any PSA decline (>0%). Mild and transient (CTCAE grade 1-2) side effects included xerostomia (72%), nausea/vomiting (69%) and bowel movement disorders (45%). CTCAE grade 3 toxicity included nausea/vomiting (6%), anemia (8%), leukopenia (5%), kidney failure (3%), thrombocytopenia (3%), and neutropenia (3%). The mean kidney dose was 2.7 Gy for the first cycle (range 0.9-5.9) i.e. 0.4 Gy/GBq (range 0.15-0.9). There was no difference between the efficacy and toxicity for the 6.0 GBq (n[23) and 7.4 GBq (n[41) treatment arms.
